Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Theralase Technologies Inc is a clinical stage pharmaceutical company. It is dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and technology platforms intended to safely and effectively; treat various cancers, bacteria and viruses. The Cool Laser Technology division designs, develops, manufactures and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, primarily in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:TLT.W)

Fundamentals Snapshot (TSXV:TLT.W)

Bullboard Posts (TSXV:TLT)

RE:RE:RE:Potential Rise

Good questions consultant - hopefully some enlightenment on the 17th.
fredgoodwinson - 18 minutes ago

RE:RE:Potential Rise

Interesting point raised about more than 2 treatments.  I have wondered if any patients so far that were NR after their first...
consultant99 - 35 minutes ago

RE:RE:RE:Potential Rise

Priority review would have been 6 months instead of 9 months, obliging the FDA to give a response now in February Vs in May?   ...
enriquesuave - 43 minutes ago

RE:RE:Potential Rise

It might not be for nothing that the FDA is going for standard review time for IBRX rather than priority review?  Although they...
enriquesuave - 45 minutes ago

RE:RE:RE:Time to Take some off the Table here? We could see the lows!

Thanks consultant99 for your thoughts, I see approx 200,000 shares for sale between $0.395 to $0.43, this could add to some selling...
InvestorRights - 47 minutes ago

RE:RE:Potential Rise

Anything is possible, but the good thing is that right after BTD, the FDA will give them guidance on possible AA and timeline may be...
enriquesuave - 51 minutes ago